AAVhu68 Vector for Fabry Disease Enzyme Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Fabry disease, such as enzyme replacement therapy, face challenges with low physical stability and variable tissue uptake of recombinant human alpha-Gal A, limiting efficacy in addressing enzyme deficiency and associated symptoms.
Innovation Solution
Development of a recombinant AAV vector using the AAVhu68 capsid to deliver a vector genome encoding a functional human alpha-galactosidase A (hGLA) with specific regulatory sequences, ensuring stable enzyme expression and targeted tissue uptake.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy is used to treat Fabry disease, then enzyme deficiency can be addressed, but the treatment suffers from low physical stability and variable tissue uptake
Solution Approach 1:
The patent uses AAVhu68 capsid as an intermediary delivery vehicle to transport the hGLA enzyme coding sequence into target tissues. This viral vector mediator solves the problem of variable tissue uptake by providing targeted delivery mechanisms while protecting the enzyme coding sequence during circulation, thereby addressing both stability and delivery efficiency issues simultaneously
2Duration of action of moving object
If recombinant AAV vector is used to deliver hGLA coding sequence, then sustained enzyme activity is achieved, but the vector design complexity increases
Solution Approach 1:
The AAVhu68 capsid serves multiple functions: it protects the enzyme coding sequence during circulation, enables targeted delivery to specific tissues, and facilitates sustained expression of hGLA. This multi-functionality reduces the need for separate protective and delivery mechanisms, thereby managing complexity while achieving sustained enzyme activity
Solution Approach 2:
The patent employs specific regulatory sequences including tissue-specific promoters and miRNA target sequences to control expression parameters. These parameter changes in the vector design enable sustained enzyme activity while the sequences are optimized to work efficiently together, managing the overall system complexity
3Reliability
If hGLA is expressed at therapeutic levels, then Fabry disease symptoms are alleviated, but the risk of immunogenicity and off-target effects increases
Solution Approach 1:
The patent uses tissue-specific promoters and miRNA target sequences to enable localized expression of hGLA in specific target tissues rather than systemic expression. This local quality approach achieves therapeutic efficacy in affected organs while minimizing exposure in non-target tissues, thereby reducing immunogenicity and off-target effects
Solution Approach 2:
The AAVhu68 capsid acts as a targeted intermediary that delivers the enzyme coding sequence specifically to desired tissues through receptor-mediated entry. This targeted delivery mechanism reduces unnecessary expression in non-target organs, lowering the risk of immunogenic responses and off-target effects while maintaining therapeutic efficacy
Data Source
AI summary
Provided herein are polynucleotide sequences encoding functional human alpha-galactosidase A (hGLA) and expression cassettes containing these coding sequences. Also provided are vectors, such as recombinant adeno-associated virus (rAAV) vectors having vector genomes that include an hGLA coding sequence operably linked to one or more regulatory sequences. Further, compositions containing these expression cassettes and rAAV are provided, as well as methods for the use of these compositions for treatment of Fabry disease.